Patents Assigned to Advaxis, Inc.
-
Publication number: 20240124540Abstract: Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains.Type: ApplicationFiled: November 21, 2023Publication date: April 18, 2024Applicant: Advaxis, Inc.Inventors: Robert Petit, Michael F. Princiotta, Brandon Coder, David Balli
-
Patent number: 11897927Abstract: Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains.Type: GrantFiled: November 30, 2017Date of Patent: February 13, 2024Assignee: ADVAXIS, INC.Inventors: Robert Petit, Michael F. Princiotta, Brandon Coder, David Balli
-
Publication number: 20230357781Abstract: This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.Type: ApplicationFiled: May 12, 2023Publication date: November 9, 2023Applicant: Advaxis, Inc.Inventors: Robert Petit, Michael F. Princiotta
-
Patent number: 11702664Abstract: This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.Type: GrantFiled: December 18, 2020Date of Patent: July 18, 2023Assignee: Advaxis, inc.Inventors: Robert Petit, Michael F. Princiotta
-
Patent number: 11446369Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.Type: GrantFiled: November 1, 2019Date of Patent: September 20, 2022Assignees: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Yvonne Paterson, John Rothman, Vafa Shahabi
-
Publication number: 20220062181Abstract: Methods and compositions are provided for lyophilization of bacteria or Listeria strains, such as Listeria monocytogenes. Provided are methods for producing a lyophilized composition comprising a bacteria or Listeria strain, formulations for lyophilization comprising a bacteria or Listeria strain, lyophilized bacteria or Listeria strains, and methods of preparing frozen bacteria or Listeria strains for lyophilization.Type: ApplicationFiled: October 18, 2021Publication date: March 3, 2022Applicant: Advaxis, Inc.Inventors: David Fela, Anu Wallecha, Mike Grace, Melissa Gosse
-
Patent number: 11179339Abstract: Methods and compositions are provided for lyophilization of bacteria or Listeria strains, such as Listeria monocytogenes. Provided are methods for producing a lyophilized composition comprising a bacteria or Listeria strain, formulations for lyophilization comprising a bacteria or Listeria strain, lyophilized bacteria or Listeria strains, and methods of preparing frozen bacteria or Listeria strains for lyophilization.Type: GrantFiled: August 29, 2018Date of Patent: November 23, 2021Assignee: Advaxis, Inc.Inventors: David Fela, Anu Wallecha, Mike Grace, Melissa Gosse
-
Publication number: 20210239681Abstract: Methods and compositions are provided for assessing antigen presentation and potency of Listeria-based immunotherapeutics in inducing an immune response.Type: ApplicationFiled: April 25, 2019Publication date: August 5, 2021Applicant: ADVAXIS, INC.Inventors: Anu WALLECHA, Mike GRACE
-
Publication number: 20210177955Abstract: Provided herein are tumor-associated antigen peptides comprising heteroclitic mutations and fusion polypeptides comprising such heteroclitic peptide. Also provided are nucleic acids encoding such peptides and fusion polypeptides, recombinant bacteria or Listeria strains comprising such peptides, fusion polypeptides, or nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such peptides, fusion polypeptides, nucleic acids, and recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such peptides, fusion polypeptides, nucleic acids, or recombinant bacteria or Listeria strains.Type: ApplicationFiled: November 8, 2018Publication date: June 17, 2021Applicant: ADVAXIS, INC.Inventors: Robert PETIT, Michael F. PRINCIOTTA, Brandon CODER, David BALLI
-
Patent number: 10900044Abstract: This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.Type: GrantFiled: March 3, 2016Date of Patent: January 26, 2021Assignee: ADVAXIS, INC.Inventors: Robert Petit, Michael F. Princiotta
-
Publication number: 20210003558Abstract: Methods and compositions are provided for assessing attenuation and/or infectivity of bacteria or Listeria strains, such as Listeria monocytogenes.Type: ApplicationFiled: March 8, 2019Publication date: January 7, 2021Applicant: ADVAXIS, INC.Inventors: Poonam MOLLI, Anu WALLECHA
-
Publication number: 20200261369Abstract: Methods and compositions are provided for lyophilization of bacteria or Listeria strains, such as Listeria monocytogenes. Provided are methods for producing a lyophilized composition comprising a bacteria or Listeria strain, formulations for lyophilization comprising a bacteria or Listeria strain, lyophilized bacteria or Listeria strains, and methods of preparing frozen bacteria or Listeria strains for lyophilization.Type: ApplicationFiled: August 29, 2018Publication date: August 20, 2020Applicant: ADVAXIS, INC.Inventors: David FELA, Anu WALLECHA, Mike GRACE, Melissa GOSSE
-
Publication number: 20200069785Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.Type: ApplicationFiled: November 1, 2019Publication date: March 5, 2020Applicants: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Yvonne PATERSON, John ROTHMAN, Vafa SHAHABI
-
Publication number: 20200061167Abstract: The subject matter described herein is directed to methods of treating, protecting against, and inducing an immune response against a human papillomavirus-associated tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain expressing a construct comprising at least one human papillomavirus antigen in combination with one or more other therapeutic agents to treat a tumor or metastatic cancer.Type: ApplicationFiled: November 7, 2017Publication date: February 27, 2020Applicant: ADVAXIS, INC.Inventors: Sandra M. HAYES, Rachelle KOSOFF, Jun ZOU
-
Publication number: 20190381160Abstract: This invention provides a system of providing and creating personalized immunotherapeutic compositions for a subject having a disease or condition, including therapeutic immunotherapy delivery vectors and methods of making the same comprising gene expression constructs expressing peptides associated with one or more neo-epitopes or peptides containing mutations that are specific to a subject's cancer or unhealthy tissue. A delivery vector of this invention includes bacterial vectors including Listeria bacterial vectors; or viral vectors, peptide immunotherapy vectors; or DNA immunotherapy vectors, comprising one or more fusion proteins comprising one or more peptides comprising one or more neo-epitopes present in disease-bearing biological samples obtained from the subject. This invention also provides methods of using the same for inducing an immune response against a disease or condition, including a tumor or cancer, or an infection, or an autoimmune disease or an organ transplant rejection in the subject.Type: ApplicationFiled: May 26, 2016Publication date: December 19, 2019Applicant: Advaxis, Inc.Inventors: Robert PETIT, Kyle PERRY, Michael F. PRINCIOTTA, Daniel J O'CONNOR
-
Publication number: 20190322714Abstract: Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains.Type: ApplicationFiled: November 30, 2017Publication date: October 24, 2019Applicant: Advaxis, Inc.Inventors: Robert Petit, Michael F. Princiotta, Brandon Coder, David Balli
-
Publication number: 20190248856Abstract: Provided are Listeria-based immunogenic compositions comprising Wilms tumor protein (WT1) antigens and methods for treating and vaccinating against cancer and inducing an immune response against the same in a subject. Also provided herein are recombinant fusion polypeptides or chimeric polypeptides comprising Wilms tumor protein antigens, nucleic acids encoding such chimeric polypeptides or fusion polypeptides, recombinant bacteria or Listeria strains comprising such chimeric polypeptides or fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such chimeric polypeptides or fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such chimeric polypeptides or fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains.Type: ApplicationFiled: June 30, 2017Publication date: August 15, 2019Applicant: Advaxis, Inc.Inventors: Michael Princiotta, Robert Petit
-
Publication number: 20190240303Abstract: The present invention provides methods of treating, protecting against and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain. In one embodiment the present invention relates to a recombinant Listeria strain, said recombinant Listeria strain comprising a recombinant nucleic add, said nucleic add comprising a first open reading frame encoding a recombinant polypeptide comprising a first N-terminal fragment of an LLO protein fused to a heterologous antigen or fragment thereof, and wherein said recombinant nucleic add further comprises a second open reading frame encoding a mutant PrfA protein.Type: ApplicationFiled: February 14, 2019Publication date: August 8, 2019Applicant: ADVAXIS, INC.Inventors: Anu Wallecha, Robert Petit
-
Patent number: 10258679Abstract: The present invention provides methods of treating, protecting against and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain. In one embodiment the present invention relates to a recombinant Listeria strain, said recombinant Listeria strain comprising a recombinant nucleic add, said nucleic add comprising a first open reading frame encoding a recombinant polypeptide comprising a first N-terminal fragment of an LLO protein fused to a heterologous antigen or fragment thereof, and wherein said recombinant nucleic add further comprises a second open reading frame encoding a mutant PrfA protein.Type: GrantFiled: April 14, 2015Date of Patent: April 16, 2019Assignee: ADVAXIS, INC.Inventors: Anu Wallecha, Robert Petit
-
Publication number: 20190032064Abstract: Disclosed herein is a personalized immunotherapy composition for a subject having a disease or condition, including therapeutic vaccine delivery vectors and methods of making the same comprising gene expression constructs expressing frameshift-mutation-derived peptides associated with one or more neo-epitopes encoded by nucleic acid sequences comprising at least one frameshift mutation, wherein the frameshift mutation is specific to a subject's cancer or unhealthy tissue. A delivery vector of this disclosure includes bacterial vectors; or viral vectors, or peptide vaccine vectors; or DNA vaccine vectors including Listeria bacterial vectors comprising one or more fusion proteins comprising one or more frameshift-mutation-derived peptides comprising one or more neo-epitopes present in disease-bearing biological samples obtained from the subject.Type: ApplicationFiled: January 27, 2017Publication date: January 31, 2019Applicant: Advaxis, Inc.Inventors: Robert PETIT, Kyle PERRY, Michael F. PRINCIOTTA